UCB upgrades 2026 guidance: UCB stock gains 14.23 percent

Published on 10/22/2026 at 09:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB upgrades 2026 revenue growth guidance to the low twenties. UCB stock costs EUR 243.30 on October 22, 2026 versus EUR 213.00 at the Xetra close.

Growth and reporting milestones

UCB upgraded 2026 revenue growth guidance to the low twenties on October 22, 2026.
BIMZELX sales reached EUR 1.52 billion in the first half of 2026.
UCB stock trades at EUR 243.30 at 9:09 a.m. CEST at Lang & Schwarz on October 22, 2026, 14.23 percent above the Xetra close of October 21, 2026.
UCB will publish full-year 2026 results on February 25, 2027.

Geometrisches Bauhaus-Poster mit Kreisen, Dreiecken und dem Schriftzug BIOPHARM in Primärfarben — UCB S.A., ISIN BE0003739530, illustriert als geometrisches Bauhaus-Poster mit Sektor-Kürzel BIOPHARM und Molekülformen, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) trades at EUR 243.30 at Lang & Schwarz on October 22, 2026 at 9:09 a.m. CEST, 14.23 percent above the Xetra close of October 21, 2026 at EUR 213.00. On October 22, 2026, UCB upgraded its 2026 financial guidance, citing stronger BIMZELX performance in the United States and continued CIMZIA volume growth.

The guidance reset is the clearest signal for UCB stock because it combines faster sales growth with operating leverage. Revenue growth is now expected in the low twenties at constant exchange rates, up from the low- to mid-teens, while adjusted EBITDA growth is expected in the low- to mid-forties, up from the mid-teens to low-twenties, according to UCB.

What does guidance mean for margins?

UCB's investor page lists BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak sales guidance above EUR 7 billion. The same page lists CIMZIA sales of EUR 954 million and RYSTIGGO sales of EUR 192 million in the first half of 2026, showing how the newer immunology portfolio is becoming more important to the revenue mix.

The upgraded outlook excludes proceeds from a Priority Review Voucher sale. UCB said those proceeds could add low- to mid-single-digit percentage points to revenue and adjusted EBITDA growth, while its disclosed risk factors include pricing pressure, biosimilar competition and regulatory uncertainty.

Three dated portfolio signals

On September 30, 2026, UCB reported that 47.4 percent of patients receiving earlier bimekizumab treatment achieved complete inflammatory-lesion resolution at three years, versus 33.3 percent among those treated later. On October 16, 2026, UCB announced U.S. FDA approval of a ZILBRYSQ autoinjector, supported by complete dose delivery in 99.8 percent of 449 administrations. On October 22, 2026, UCB upgraded its 2026 revenue growth outlook to the low twenties.

When is the next reporting date?

UCB will publish full-year 2026 results and formal 2027 guidance on February 25, 2027. For investors, that release will test whether the stronger BIMZELX and CIMZIA trajectory is translating into the adjusted EBITDA expansion now embedded in guidance.

Stock reprices the guidance

UCB stock trades at EUR 243.30 at Lang & Schwarz on October 22, 2026 at 9:09 a.m. CEST, 14.23 percent above the Xetra close of October 21, 2026 at EUR 213.00. The EUR 40.6 billion market capitalization and EUR 197.45 to EUR 289.50 52-week range put the move in a broader valuation context.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.